Article Sidebar

pdf
Date Published: 09/04/2025
Abstract Views: 110
Views pdf: 72
DOI: https://doi.org/10.51298/vmj.v548i1.13328
Issue
Vol. 548 No. 1 (2025)
Section
Các bài báo
How to Cite
Quách Thanh, D., Đào Thị Thu, T., Nguyễn Đình, T., Trần Thành, T., & Vũ Huy, H. (2025). OSIMERTINIB PLUS CHEMOTHERAPY IN FIRST-LINE TREATMENT FOR EGFR-MUTANT, METASTATIC NON-SMALL CELL LUNG CANCER. Vietnam Medical Journal, 548(1). https://doi.org/10.51298/vmj.v548i1.13328

OSIMERTINIB PLUS CHEMOTHERAPY IN FIRST-LINE TREATMENT FOR EGFR-MUTANT, METASTATIC NON-SMALL CELL LUNG CANCER

Dung Quách Thanh, Trang Đào Thị Thu, Tùng Nguyễn Đình, Tín Trần Thành, Hoàng Vũ Huy

Main Article Content

Abstract

Osimertinib- a third-generation EGFR inhibitor is the first prefered option and it is often used as a monotherapy in the first-line treatment of EGFR- mutants metastatic non-small cell lung cancer. Recently, with the evidence from the FLAURA 2 study showed that the combination of Osimertinib with chemotherapy was more effective than Osimertinib monotherapy, especially in patients with central nervous system (CNS) metastases at baseline. However, the side effects of treatment as well as the high cost are also a big burden for patients, so currently not many patients are using this combination regimen. This report aims to describe the clinical, subclinical and initial treatment results of EGFR- mutant, Non-small cell lung cancer cases treated with Osimertinib plus chemotherapy at Vinmec Oncology Center.

Article Details

Keywords

Non-small cell lung cancer, EGFR mutation

References

1. GLOBOCAN 2020: New Global Cancer Data | UICC. Accessed October 8, 2023. https://www.uicc.org/news/globocan-2020-new-global-cancer-data
2. J. Greenhalgh, K. Dwan, A. Boland, V. Bates, F. Vecchio, Y. Dundar, P. Jain, J.A. Green, First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer, Cochrane Database Syst Rev (5) (2016) Cd010383.
3. Zhang, Y.L. Yuan, J.Q. Wang, K.F. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016; 7:78985-78993.
4. Anh- thu Huynh Dang, Vu-Uyen tran, Thanh-Truong chan, et al. Actionable Mutation Profiles of non-Small cell Lung cancer patients from Vietnamese population. Sientific Report 2020, 10:2707.
5. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378:113.
6. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. The New England journal of medicine. Jan 2 2020; 382(1):41-50. doi:10.1056/ NEJMoa1913662.
7. Planchard D, Jänne PA, Cheng Y, et al. for the FLAURA2 Investigators. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med 2023; 389:1935-1948
8. Saito, H., Fukuhara, T., Furuya, N., Watanabe, K., Sugawara, S., Iwasawa, S., et al. (2019). Erlotinib Plus Bevacizumab Versus Erlotinib Alone in Patients with EGFR-Positive Advanced Non-Squamous Non-Small-Cell Lung Cancer (NEJ026): Interim Analysis of An Open-Label, Randomised, Multicentre, Phase 3 Trial. Lancet Oncol. 20 (5), 625–635. doi:10.1016/S1470-2045(19)30035-X
9. Hosomi, Y., Morita, S., Sugawara, S., Kato, T., Fukuhara, T., Gemma, A., et al. (2020). Gefitinib Alone versus Gefitinib Plus Chemotherapy for Non-small-cell Lung Cancer with Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J. Clin. Oncol. 38 (2), 115–123. doi:10.1200/JCO.19.01488
10. Mok T.S., Wu Y.-L., Ahn M.-J. et al., Osimertinib or Platinum–Pemetrexed in EGFR T790M Positive Lung Cancer. N Engl J Med, 376(7), 2017, 629–640.